Turning Point Ther.

$44.70 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Turning Point Ther.

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Stock Analysis

last close $46.83
1-mo return -40%
3-mo return -30.6%
avg daily vol. 589.12T
52-week high 141.3
52-week low 42.51
market cap. $2.3B
forward pe -
annual div. -
roe -17.6%
ltg forecast -
dividend yield -
annual rev. $55M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe